What are effects of TNFi on Lipids in AxSpA? Ab#0531 #ACR23 @RheumNow 320 pts w AS - retrosp cohort, first-line TNFi, not on lipid Rx Chol and TG increase in 1st 3 mos of treatment. LDL & HDL: no signif change Inflam markers/Lipids correlated - suspect due to anti-inflamm effect https://t.co/qT5qUEOEvO

Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

#CV risk in #AxSpA in Korean population study N=71001, age 42, 71%M but 16% #MTX, 58% #SSZ. #TNFi vs none 30% less CVE. IL17 NO CV reduction but ?confounded by line of #Rx and v large N for TNFi. Study stated PRIOR to IL17i approval #ACR23 @ACRheum @RheumNow L11 poster ?Rx bias https://t.co/3Sft5KUlLa

Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS

I never tire of hearing this story. Biologic DMARDs revolutionized rheumatology & changed millions of lives. How did we get TNFi? Sharp translational insights & courage++ After 4w, RA gone, up/down stairs like a miracle. Sir Ravinder 'Tiny' Maini #ACR23 Global Summit @RheumNow https://t.co/Je1cz3cWG5